Skip to content

Management of Rheumatoid arthritis through Panchakarma therapy

Virechana karma along with Vaitarana Basti followed by Maha Bhallataka Avaleha in the managementof Amavata w.s.r. to Rheumatoid Arthritis - A Comparative Rondomized Controlled Study - CRCS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/012115
Enrollment
40
Registered
2018-02-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PATIENTS WHO ARE SUFFERING FROM SYMPTOMS OF AMAVATA

Interventions

Intervention1: panchakarma internal medicaiton: Virechana. Vaitaranabasti, Internal medication as maha bhallataka avaleha, aswagandha, simhanada guggulu for 12weeks Intervention2: internal medicaion:

Sponsors

Institute for Post Graduate Teaching and Research in Ayurved jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient who is born and grown up in India 2. Willing and able to perticipate in the study 3. Patient having sign and symptoms of Amavata 4. Patinet who has Rheumatoid Arthritis with fullfill Diagnostic criteria(RF, ANTI CCP, ESR) 5. Chronicity less than 7 years PATIENTS FIT FOR PANCHAKARMA THERAPY 6. PATIENTS WHO IS POSITIVE IN ACR/EULAR TEST AND ACR SCORE

Exclusion criteria

Exclusion criteria: (1)Patients having severe systemic illness such as: Cardiac failure. (2)Patients below 18 year and above 60 years (3)Pregnant/lactating women (4)Chronicity more than 7 and more years (5)Active or chronic hepatitis (6)Patient born and grownup in other than India (7)Patient not fit for Panchakarma therapy

Design outcomes

Primary

MeasureTime frame
1. Change in the DAS28-CRP or DAS-ESR 2.Change in the SF-36 3.Change in the Ayurvedic Parameters for Amavata and Agni. Timepoint: 84 weeks

Secondary

MeasureTime frame
to evaluate the efficacy of differenet varieties of ayurvedic treatment in the management of amavata(rheumatoid arthritis)Timepoint: RA Factore Anti-CCP DAS 28

Countries

India

Contacts

Public ContactShiho oikawa

MD scholar

banzai_oikawas@yahoo.co.jp9737517756

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026